RANI logo

RANI THERAPEUTICS HOLDINGS-A

RANINASDAQ
πŸ† #4344 by market capEarnings Mar 25US Equity
$0.51β–Ό $0.07 (βˆ’11.97%)
Market closed Β· at close
πŸ””
Track RANI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 12.0%
7dβ–Ό 3.4%
14dβ–Ό 5.7%
30dβ–Ό 15.7%
ytdβ–Ό 62.3%
1yβ–Ό 68.7%
🏦Market Cap
$33M
Small Cap
πŸ“ˆRevenue Growth (YoY)
58.9%
High Growth
πŸ“ŠGross Margin
97.5%
High
πŸ’΅FCF Margin
-352.7%
Thin
βš–οΈP/S Ratio
5.1x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.51 – $0.58
52-Week Range
$0.50 – $1.69
Volume (shares)
459,003
Avg Volume (shares)
β€”
Shares Outstanding
65.3M
Next Earnings
2027-03-25

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$2M
P/E Ratio
-2.7
P/S Ratio
5.1x
EPS (TTM)
$-0.16
Dividend Yield
0.00%
Dilution (1yr)
+350.4%
RANI logo

RANI THERAPEUTICS HOLDINGS-A

RANI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2Mβ–² +58.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
44.9%β–Ό βˆ’55.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$38Mβ–Ό βˆ’28.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$19Mβ–Ό βˆ’47.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
147.1Mβ–² +350.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$14Mβ–² +$40M YoY
StockOtter Β· stockotter.space

About RANI THERAPEUTICS HOLDINGS-A

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy2
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.